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The Schnitzler Syndrome (SchS) is an acquired, autoinflammatory condition successfully
treated with IL-1 inhibition. The two main defining features of this late-onset condition are
neutrophilic urticarial dermatoses (NUD) and the presence of an IgM monoclonal
component. While the former aspect has been extensively studied in this disease
setting, the enigmatic paraproteinaemia and its potential consequential effects within
SchS, has not previously been thoroughly addressed. Previous studies analyzing clonal B
cell repertoires have largely focused on autoimmune disorders such as Systemic Lupus
Erythematous (SLE) and hematological malignancies such as Chronic Lymphocytic
Leukaemia (CLL), where B-cell clonality is central to disease pathology. The present
study uses next-generation sequencing to provide detailed insight into aspects of B cell
VDJ recombination and properties of the resulting immunoglobulin chains. An overview of
IgH regional dynamics in 10 SchS patients, with a particular focus on CDR3 sequences
and VDJ gene usage is reported, highlighting the presence of specific B cell expansions.
Protein microarray detected a substantial proportion of autoreactive IgM to nuclear target
proteins, though a single universal target was not identified. Together, these genetic and
functional findings impart new understanding into this rare disorder.
Keywords: Schnitzler Syndrome, B cell repertoire, autoinflammatory diseases, paraprotein, IgMINTRODUCTION
Systemic autoinflammatory disorders (SAID) are a group of conditions, principally caused by a
dysregulated innate immune system, with neutrophils and monocytes being the central effector
cells, and defined by the lack of adaptive immune involvement, particularly without a role for
autoantibodies. The Schnitzler Syndrome (SchS) is thought to be an acquired condition with all the
cardinal features of SAID, but with one further characteristic—the presence of IgM paraproteinorg December 2020 | Volume 11 | Article 5690061
Pathak et al. Role of IgM Paraprotein in the Pathogenesis of SchS(>98% of cases). This is a very rare disored with fewer than 300
cases reported in the literature (1). The defining features of SchS
include rashes (neutrophilic urticarial dermatosis), fever, bone
pain, paraproteinemia, and excellent symptomatic response to
anti–IL-1 blocking therapies. The latter feature, in particular, is
suggestive of shared aetiology with Cryopyrin (NLRP3)–
associated periodic syndrome (CAPS or NLRP3-AID), which is
an inherited or, in rare circumstances, an acquired disorder
associated with gain of function mutations in NLRP3 leading
to uncontrolled release of IL-1. However, extensive studies have
failed to demonstrate the presence of NLRP3 mutations
(hereditary or somatic) in SchS patients (2, 3). In the majority
of SchS patients the presence of paraprotein is due to underlying
monoclonal gammopathy of undetermined significance
(MGUS). A small proportion of patients (up to 20%) go on to
develop frank lymphoproliferative disorders (LPD) including
Waldenström’s Macroglobulinaemia (WM) (1, 4) and this
association suggests an alternative cause for SchS. For example,
somatic gain of function mutations in adaptor protein MYD88
(in particular p.L265P variant) have been closely linked with the
aetiology of WM (5) and MyD88-mediated cellular pathways
provide a biological link with IL-1 signaling. However, our recent
study found that only 9/30 SchS patients carry the p.L265P
MYD88 variant (1). Furthermore, the same study found that
SchS patients did not demonstrate increased incidence of clonal
hemopoiesis, which has previously been linked with enhanced
pyroptosis (inflammatory cell death) and NLRP3 activation
(2, 6).
In addition to the lack of evidence for a genetic origin of SchS,
the precise role of paraproteinaemia in this condition has not
been fully investigated. Even when the underlying cause of
paraprotein is MGUS, a non-malignant state frequently
observed in SchS patients, the paraprotein alone can occasionally
cause significant clinical consequences. A range of such clinical
disorders with predominantly dermatological manifestations, for
example, cryoglobulinemic vasculitis and acquired C1-inhibitor
deficiency, have collectively been referred to as monoclonal
gammopathy of cutaneous significance (7). In the case of Cold
Agglutinin Disease (CAD), in the context of low-grade LPD for
example, IgM paraprotein has uniform epitope specificity
targeting red blood cells and causing their destruction (8). By
definition, almost all SchS patients have a monoclonal IgM
gammopathy mainly associated with a kappa light chain,
suggesting that a similar autoreactive phenomenon could be
involved in disease pathogenesis. A previous study indicated
that IgM skin deposits played a role in the pathophysiology of
the rash (8), but subsequent review of 83 skin biopsies, which
included staining for immune deposits, found IgM deposition in
only 23% of samples (1).
Several methods can be used to investigate the antigenic binding
properties of the SchS related paraprotein. In the case of SchS where
there are no prior apparent clues to the nature of self-antigen, a non-
restrictive, unbiased, proteome-wide approach is a reasonable initial
step. Similar protein microarray technology has been used
successfully in the past to identify relevant autoantibody targets in
autoimmune diseases (9). At the same time, High Throughput
Sequencing (HTS) can be employed to analyze the variety of theFrontiers in Immunology | www.frontiersin.org 2B cell repertoire. This is achieved by analyzing the V (Variable), D
(Diversity), and J (Junctional) (VDJ) segment composition of the
immunoglobulin heavy chain (IgH) and by determining the amino
acid sequence of the region most important for antigen binding,
complementarity determining region 3 (CDR3). Preferential
expansion of B cells with specific VDJ gene segments may result
in a restricted immune repertoire thereby constricting diversity, as
potential specificities to antigens are reduced (10). Increased usage
of specific VDJ genes are known to be a feature of autoimmune
diseases such as rheumatoid arthritis and systemic lupus
erythematous (SLE), where a bias toward IGVH4 has been
demonstrated (11, 12). With LPD’s such as WM and CLL
overrepresentation of IGHV3 has been reported (13, 14). The
potential value of studying B cell clonality in SchS patients is two-
fold. This analysis might provide circumstantial evidence that there
is a common antigenic target of the IgM paraprotein and
furthermore and, diagnostically, increasing B-cell clonality might
be predictive of progression to LPD.
In this study, we used the combination of protein microarray,
direct target interrogation and high-throughput sequencing of
the IGH regions to determine the antigen specificity of SchS
related paraprotein. Our analysis demonstrate that, while SchS
patients show evidence of a skewed IGH repertoire, the
composition of common antigenic targets exclusive to SchS, if
these indeed exist, remain elusive.METHODS
Ethics and Patients
Informed, written consent was obtained from the participants of
this study in accordance with the Declaration of Helsinki.
Genomic DNA was extracted from peripheral blood of 10 SchS
patients for IGH repertoire analyses. Serum was isolated from the
peripheral blood of another three SchS, two WM, and one
NLRP3-AID patient for IgM isolation.
Tables 1 and 2 show the demographic and clinical features of
SchS and disease control groups used in the IgM array analysis
and IGH repertoire sequencing.
IGH Repertoire Sequencing
Leader sequence and JH consensus primers (appendix) containing
Nextera linkers were used to amplify the IGH region from 10 SchS
patients’ genomic DNA, which was isolated from whole blood. A
second PCR added the Nextera sequencing adaptors and indices
(Illumina) onto the purified IGH amplicons. Details regarding the
primers, thermocycling conditions, agarose gel electrophoresis,
and gel purification are described in the supplemental methods.
The concentrations of the individual libraries were determined by
pico-green fluorescence using the Quant-iT™ dsDNA Assay Kit
(Invitrogen, USA) with the size of the final amplicons (~700 bp)
and purity determined using the Agilent 2200 TapeStation system
(Agilent Technologies, UK). Sequencing was carried out by the
NGS facility within the Leeds Institute of Medical Research at St
James’s Hospital, UK. NGS was performed on an Illumina MiSeq
sequencing instrument (Illumina,UK),witha600cycle (2×300bp)
paired-end run, according to the manufacturer’s instructions.December 2020 | Volume 11 | Article 569006
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(.fastq) files as the final output.
Bioinformatics and Analyses
The resulting.fastq files were subject to downstream processing,
analysis, and visualization. The following NGS platforms are
open access web-based programs and used sequentially in this
work: www.usegalaxy.org; www.imgt.org; and www.bioinf-
galaxian.erasmusmc.nl/argalaxy. Supplementary Figure 1
portrays how these bioinformatics tools are utilized, starting
from the Illumina MiSeq generated fastq file (Galaxy), to the
generation of CSV files for use with Microsoft Excel (15), and
finally to the downloadable graphs and plots generated by AR
Galaxy pertaining to VDJ and CDR3 properties.





IgM isolation and subsequent purification of serum samples was
carried out using the ÄKTA™ Pure system (GE Healthcare, UK) at
4°C, using prepacked HiTrap™ IgM Purification HP column as theFrontiers in Immunology | www.frontiersin.org 3stationary phase. IgM containing fractions were pooled; protein
purity was assessed by SDS-PAGE and subjected to fluorometric
quantitation using Qubit (ThermoFisher Scientific, UK).
Protein Microarray
Isolated IgM were incubated with the HuProt™ array comprised
of GST tagged proteins covering 75% of the human protein
coding genome (Cambridge Protein Arrays, UK). IgM (15 µg/
ml) from one NLRP3-AID, two WM, and three SchS samples
were applied to the array. Following incubation of IgM, anti-
human IgM Alexa Fluor IgM-488 (ug/ml) and anti-GST-
Dylight-650 (0.5 ug/ml) were applied to the array in order to
detect IgM and the embedded proteins (serving as a positive
control). A seventh slide with no IgM antibody incubated was
included as the negative control. The slides were washed and
imaged with the Tecan LS400 microarray scanner. Resulting data
were processed and analyzed using GenePix software (Molecular
Devices, USA).
For each protein on the sample array, average fluorescence
signals, and standard deviations (SDs) were calculated for the
duplicate spots of each protein. Average fluorescence signals
obtained from the corresponding protein on the negative control
array were subtracted, yielding corrected protein specificTABLE 2 | Clinical data and previous findings pertaining to the SchS patients included in the IgH repertoire sequencing work.
























4 male 36.8 16.8 4.0 IgMk 3 Partial No overt LPL No
5 male 43.9 8.7 6.0 IgGl N/A complete 15% plasma
cell
No
6 female 44.8 17.1 12.0 IgMk 1 complete No overt LPL No
7 female 49.6 8.4 8.9 IgMk 4 complete not done No
8 male 52.8 15.3 4.5 IgMl
(IF)
N/A complete No overt LPL No





10 male 59.6 13.3 7.9 IgMl 7 died before
treatment
No overt LPL No
11 male 61.7 13.3 Not avail IgMk 5 complete No overt LPL No
12 female 68.4 21.3 14.0 IgMk 8 complete No overt LPL No
13 male 78.9 13.6 14.3 IgMk 7 complete No overt LPL L265PDecember 2020 | Volume 11 | ArticlIF, Immunofluorescence; VAF, Variant allele frequency; LPL, lymphoproliferative lymphoma.
*here is used as a standard way to mark the effects of mutation.TABLE 1 | Patients included in the IgM isolation and protein array experiments.




IgM subtype (kappa or lambda) IgMk para-protein levels (g/l) Isolated IgM levels
(g/L)
SchS-1 43.5 F Yes IgMk 16.7 0.55
SchS-2 60.7 F No IgMk 9 0.73
SchS-3 51.0 F Yes IgMk 14 0.33
WM-1 N/A M Yes IgMk 7.4 0.33
WM-2 N/A F Yes IgMk 8 0.61
NLRP3-AID N/A M N/D N/A 1.56* 0.28*polyclonal IgM levels.e 569006
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transformed, yielding log2 (Sample-Control). Finally, z-scores
were calculated for each protein on the array, to determine signal
significance within the signal distribution: z = (log2 (Sample-
Control) − average log2)/SD log2. Those proteins with z-scores
above 2.5 were deemed as likely interactors.RESULTS
BCR Repertoire Analysis
We used HTS of the IGH region of 10 SchS patients’ genomic
DNA, in order to address the hypothesis that SchS patients
exhibit a biased IGH repertoire. The IMGT numbering system
was used for CDR3 identification and annotation (16). In this
work, a clone is defined as a unique CDR3 sequence appearing in
more than 2% of the total CDR3 sequences per individual based
on previous cut-off values described by Tak et al. (>2.5%–5%)
(17). Given the potential diversity of B-cell receptors generated
by VDJ recombination (17), the rare probability of converging
upon the same rearranged IGH sequence renders each CDR3
amino acid (AA) sequence as a unique tag for a B-cell clone (18).
From the data shown in Figure 1, each SchS sample shows
increased usage of specific CDR3 AA rearrangements above the
2% limit for clonality, though to varying degrees. SchS-9 and
SchS-12 show particular skewing of the IGH repertoire
indicating a highly oligoclonal rearrangements. Imperatively,
no public CDR3 sequences were found in this dataset and
therefore the AA sequences are unique to each participant
(Supplementary Table 1).
CDR3 Analysis
The length of the CDR region varied from 9 AA (sample 5) to
24 AA (sample 7), with the median value being 15 AA,Frontiers in Immunology | www.frontiersin.org 4comparable to healthy individuals (Supplementary Table
1). The median CDR3 lengths across the individual 10 SchS
patients was either 13, 14, or 15 AA, with range between 3 and
31 AA (Figure 2). A large amount of published data
demonstrates that the majority of “healthy” CDR3 lengths
are between 8 to 18 AA with median values of 15 AA to 16 AA
(19, 20), one to two AA longer than the median values found
within SchS patients (Figure 2). The grand average of
hydropathicity index (GRAVY) value represents the
hydrophobicity of a given peptide. This formula calculates
the sum of the hydropathy values of each AA in a sequence
divided by the sequence length (based on the values provided
by Kyte and Doolittle) (21). Positive GRAVY scores indicate
the hydrophobic nature of the peptide, whereas negative
scores denote hydrophilicity. Though the values obtained
for the clones in this SchS data set were in the range of
−1.54 and +0.66, 81% demonstrated a negative score
indicating that the clones seen in this set of SchS are largely
hydrophilic (data not shown).
The CDR3 AA compositions obtained for the SchS patients
were largely comparable to the peripheral blood of 33 healthy
controls and the cord blood of 10 newborns (19) (Figures 3A, B).
Both SchS patients and healthy controls frequently use, arginine,
aspartic acid, tyrosine, glycine and alanine within their
CDR3 regions.
VDJ Analysis
Within the clonal repertoire (Supplementary Table 1), 78% of
the CDR3 AA sequences utilized the IGHV3 family, with IGHJ4
and IGHJ6 being the most common J families among these
sequences. IGHD1 and IGHD6 were the most utilized D families.
Among the entire repertoire, IGHV3 genes are the most
commonly employed segments (55%–88%) in nine out of the
10 SchS patients surveyed, whereas patient 13 more commonlyFIGURE 1 | Frequency distribution of all CDR3 AA sequences identified per SchS patient (n = 10). Each bar is representative of one patient. Each color stripe is
representative of a unique CDR3 found within that sample, with bar thickness pertaining to the frequency of that CDR3 AA sequence.December 2020 | Volume 11 | Article 569006
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and IGHD6 were the most frequently used gene families in seven
out of the 10 samples (4–8, 11, 22), with a 25% usage each.
Patient 9 preferentially employed IGHD1 at 40%, patient 12
using IGHD2 at 29% and patient 13 used both IGHD1 and
IGHD3 at 26% and 25%, respectively. Each of the 10 SchS
patients followed the same IGHJ usage patterns in their
repertoires with IGHJ4 being the most frequent J gene used
within the range of 40% to 90% (Figure 4).Frontiers in Immunology | www.frontiersin.org 5The plots shown in Figure 5 are a visual representation of the
IGHV-IGHJ rearrangements and clearly denote overrepresentation
of specific pairings. Although the prevalence of certain V-J
combinations is not entirely indicative of clonality (i.e., clonal
populations of B cells), preferential usage of particular gene
segments points toward a skewed B cell repertoire. The light blue
and navy blue arcs located within the bottom half of the circos plots
denote the IGHJ4 and IGHJ6 families respectively (in sample 13, the
navy blue arc represents the prevalent IGHJ5). The IGHV family
arcs, within the top half of the plots are in clockwise order of most
employed IGHV segment to the least. For each sample, the red and
orange ribbons demonstrate the most frequent recombination
within each patient. Samples 4, 5, and 7 preferentially pair the
IGHV3/IGHJ4 and IGHJ6 families, whereas samples 6, 8, and 10
have a preference to joining IGHV6/IGHV3 to IGHJ4 and IGHJ6.
A substantial portion of the IGH repertoire in SchS 9, 11, and 12 is
restricted to IGHV3/IGHJ4 pairings, and in contrast to the other
nine samples, sample 13 exhibits enhanced familial pairing of
IGHV6/IGHV4 to the IGHJ4 and IGHJ5 genes.
Figure 5B compares circos plots from a healthy control, SchS
patient 12 and a CLL patient. A diverse IGH repertoire is seen in
the HC, in stark contrast to the CLL sample where clear
overrepresentation of IGHV4-34 to IGHJ6 is demonstrated—
resulting from the clonal expansion of a single B cell. Among the
10 SchS samples, samples 9 and 12 are the most clonal in terms of
the increased frequency of specific IGH CDR3 clones (Figure 1
and Supplementary Table 1). Comparison sample 12 to HC and
CLL illustrates a more than one disproportionate V-J gene
rearrangement (for example, IGHV3-11 to IGHJ4), but not to
the single clonal expansion seen in CLL and is more visually akin
to the HC plot.
It is well established in lymphoma that there is a restricted
range of B cell receptor stereotypes. Using the AResT algorithm
we tried to identify these patterns in the 50 largest B clones in the
SchS patients. Among the patients only one, patient 5, hadA
B
FIGURE 3 | (A, B) Comparison of 10 SchS CDR3 AA composition (A) with
the compositions of 2 sets of data derived from the literature (B).
(B) represents healthy controls (n = 33) vs. neonates (n = 10). Figure 4B
obtained from Hong et al. (18).FIGURE 2 | The CDR3 length data comparison obtained from the 10 SchS patients included in this work. The whiskers denote the ranges, with the interquartile and
median values indicated by the boxes.December 2020 | Volume 11 | Article 569006
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(CLL#14, IGHV4-4, CDR3: CARLRAGAFDYW); this clone
represented only 0.25% of the total repertoire.
A Proteome-Wide Approach for
Identifying IgM Binding Targets
Although the BCR repertoire analysis did not demonstrate
evidence of shared clonality among SchS patients, the skewed
usage of particular VH genes may be consistent with recognition
of a common antigen. To further test the hypothesis that the
monoclonal IgM component binds to a specific protein or set of
related proteins we employment of an unbiased and proteome-Frontiers in Immunology | www.frontiersin.org 6wide approach using isolated IgM as the probing sample. All
patient samples were suitable for HuProt™ analysis with no
background observed and showed a moderate strength of
microarray spot interaction as indicated by the z-scores and
i-scores, except for SchS-3 which demonstrated strong binding
(For comprehensive list of protein array hits for all patients and
controls, please see Supplementary Table 2). The initial analysis
was restricted to the top twenty hits for each sample. This
approach failed to identify a common target between all three
SchS patients. The protein array was positive for a number of self-
antigens, with two out of the three SchS patients and one WM
patient sharing five common target proteins (ATF-1A
B
FIGURE 5 | (A, B) (A) Circos plots demonstrating the frequency at which a V-J combination is used. The colors indicate those V-J combinations pertaining to more
than 1% of the total nucleotide sequences observed, whereas the gray lines correspond to combinations constituting less than 1%. The greater the width of the
ribbon, the higher the frequency of that particular VH gene combined with a specific JH gene (B). comparison of representative HC and CLL circos plots with SchS.A
B
C
FIGURE 4 | (A–C) Bar charts summarizing VH, DH, and JH gene usage in the SchS cohort. The percentage of sequences are on the Y axis with the sample
number on the X axis. VH, DH, and JH usages are shown as the percentage of sequences on the Y axis.December 2020 | Volume 11 | Article 569006
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(chromatin assembly), DPP10 (peptidase), and SSH3 (protein
phosphatase). H2AFY (transcriptional repressor) was a shared
hit with both SchS-1 and SchS-2 (Figure 6). However, there were
no common targets shared by all 3 SchS patients. Notably,
autoimmune related hits were largely found in SchS patients
(e.g. SRSF7, SART3, OGFR H2AFY, and COL4A5), indicating a
SchS-IgM preponderance to recognizing self-proteins. Both SchS
and WM patients demonstrated over 90% of their top 20 hits as
nuclear, whereas NLRP3-AID-IgM was directed toward both
nuclear and plasma membrane associated proteins. A
significant proportion of these intracellular targets included
transcription factors and transcriptional activators; regulators
of chromatin and RNA related proteins. In contrast, extracellular
antigens were largely absent with all samples. Having failed to
identify a common protein shared by all SchS patient we then
broadened the search. We included all interacting proteins which
had z-scores above 2.5, since this technically still suggested
meaningful interaction, but limited the analysis to extracellular
ormembraneboundproteinsonly, sincephysiologically thesewere
the most plausible targets. Apart from DPP10 (Dipeptidyl
peptidase 10), which now appeared in all SchS but not in the
NLRP3-AID sample (1 WM samples was positive on initialFrontiers in Immunology | www.frontiersin.org 7analysis), no other common targets for found for all ShsS
patients following this extended search.DISCUSSION
Uniquely, among SAID, SchS is characterized by the presence of
paraprotein. This study set out to investigate the role of the
paraprotein and related clonal B cell population in the aetiology
of this condition. We hypothesized that SchS derived IgM
paraproteins have common self-antigenic targets, the binding of
which leads to pathobiological effects, and consequent
clinical manifestations of the condition. To explore this notion,
we performed deep sequencing of the IGH regions from 10 SchS
patients to determine if there is evidence of shared B cell clonality,
which would imply that the manifesting paraproteinaemia may bear
the same antigenic property. Furthermore, we interrogated the
binding properties of the IgM isolated from three SchS patients.
We used two disease controls, WM since these patients have
IgM paraprotein, but no overt inflammatory complications, and
NLRP3-AID, a SAID that clinically resembles SchS, but with
no paraproteinemia.FIGURE 6 | IgM targets. The top 20 hits found within samples SchS-31, NLRP3-AID-7, and WM-1 are exclusive to each patient; whereas SchS-2, SchS-23, and
WM-2 share common target.December 2020 | Volume 11 | Article 569006
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the aetiology of LPD and autoimmune diseases is complex. There
is an increased incidence of LPD in systemic autoimmune
diseases (15), which is thought in part to result from
continuous stimulation by autoantigens and consequent
narrowing of the B cell repertoire (23, 24). On the other hand,
chronic self-antigen stimulation has been postulated in the
aetiology of LPD. In case of CLL, the malignant B cell clones
express very restricted BCR repertoire suggesting that antigenic
pressure plays a part in selection of specific clonotypic BCR IG
(25). However, a common antigen for LPD has been challenging
to find. For example, in one study, WM-IgM was found to be
directed at several self-antigens including polysaccharides, lipids,
and DNA (26). Another study also looking into the
immunological properties of the paraproteinaemia produced in
both MGUS and MM also found no universal hits (27).
When considering CAD as an example of LPD associated
with IgM paraproteinemia and a defined antigenic targets,
previous studies have shown that deep sequencing
methodologies can be used to identify particular IGH
repertoire(s) associated with this phenomenon. A similar
approach was taken in this study. Through analysis of the
three general metrics of B cell repertoire skewing: CDR3 length
distribution, CDR3 AA composition, and VH gene usage we
found various degrees of B cell clonality in each individual case
but we did not demonstrate shared B cell clonality among SchS
patients. While both clonal and total populations demonstrated
CDR3 lengths and AA compositions comparable to healthy
controls (19), preferential usage of specific V, D, and J genes
alongside biases in recombination of the latter segments points
toward evidence of clonal B cell populations present in these
patients. However, the degrees to which these clonal populations
exist are different for each SchS patient. Presently, it is unclear if
these differences could predict those patients who are greater risk
of developing overt LPDs such as WM as documented in 20% of
SchS patients.
To determine if autoantigens have a role in pathogenesis if
SchS we used the protein microarray which contains around 75%
of the annotated human protein coding genome with nearly 90%
of the expressed proteins being at full-length. Interestingly, one
self-antigen which was recognized by all SchS patients was
DPP10. DPP10 is a dipeptidyl peptidase-like membrane
protein expressed in multiple tissues (28). Physiologically,
DPP10 is a plausible target since this protein is able to
modulate type-A potassium channels (29). The potassium
efflux is one of the main triggers for NLRP3 activation, and
therefore hypothetically IgM paraprotein binding to DPP10
could affect the potassium flux and contribute to the activation
of NLRP3. Moreover, DPP10 polymorphisms have been linked
to asthma and knockdown of DPP10 in bronchial epithelial cells
altered responses to IL-1 stimulation (28, 30). However, DPP10
was also one of the targets which was positively identified by the
IgM originating from a patient with WM, who we later
confirmed did not have any inflammatory symptoms.
Further analysis found four common targets shared by two
SchS and one WM patient, while generally, SchS patients showed
more self-reactive profile compared to control NLRP3-AIDFrontiers in Immunology | www.frontiersin.org 8patient. The vast majority of all positive interactions was with
proteins that have either nuclear or cytosolic location. While the
overarching function of the shared proteins could be broadly
linked to cellular growth and pro-survival, their disparate
functions and intracellular locations essentially indicate they
do not belong to a specific pathway or collectively serve a
combined purpose. Furthermore, considering that under
physiological conditions, IgM cannot penetrate the cell, the
relevance of these interactions is even more uncertain.
Nevertheless, similar autoantibodies directed to the nuclear
material, for example, are seen in SLE. The generation of these
autoantibodies, in part, is triggered by dysregulated apoptosis
and impaired clearance of the cellular debris (31). In the case of
SchS enhanced inflammasome activation is well-documented.
This, in turn, would result in increased pyroptosis and release of
the cellular content thus facilitating the development of a more
self-reactive IgM repertoire. However, these results can also be
explained by the fact that total, rather than monoclonal only
components of IgM were tested on the microarray. This could be
resulted in non-specific, low-affinity interactions, which are
generally more common with IgM compared to IgG.
The experimental evidence garnered in this work does not
support the notion of an antigen-driven pathogenesis for SchS,
though the suggestions of clonal B-cell populations
underscores the role of the adaptive branch of the immune
system within this autoinflammatory condition. However, the
focus of our study was on sequencing B cell form peripheral
blood, therefore it is possible that important B cell clones
residing either in bone marrow, or secondary lymphoid
organs would be missed by this approach. The development
of lymphoproliferative disease occurs in 20% of patients, thus it
is plausible to suggest that the evidence of B-cell clonality
documented in SchS may be representative of different stages of
pre-malignant evolution, co-existing with the “normal” B-cell
repertoire. Such B-cell clones would further require malignant
transformation—an event not occurring in all SchS patients.
Whether the supposed event is genetic (i.e., mutations) or due
to epigenetic defects remains to be explored. Nevertheless, close
monitoring of SchS patients is imperative to detect progression
to WM or other overt LPD development. Longitudinal analysis
of the expanded CDR3 AA clones within these patients could
be one approach to determine whether the latter are, in part,
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